Mon panier

Siglec-15

Siglec-15 Informations sur la molécule

Nom anglaisSialic acid-binding Ig-like lectin 15Nombre de médicaments commercialisés0
Nombre de médicaments cliniques3Alias de la cibleSIGLEC15,Sialic Acid Binding Ig Like Lectin 15,CD33 Antigen-Like 3,CD33L3,Sialic Acid-Binding Ig-Like Lectin 15,SIGLEC-15,HsT1361,CD33 Molecule-Like 3,Sialic Acid Binding Ig-Like Lectin 15
Phase de R&D la plus avancéePhase 2 Clinical
Nom anglaisSialic acid-binding Ig-like lectin 15
Alias de la cibleSIGLEC15,Sialic Acid Binding Ig Like Lectin 15,CD33 Antigen-Like 3,CD33L3,Sialic Acid-Binding Ig-Like Lectin 15,SIGLEC-15,HsT1361,CD33 Molecule-Like 3,Sialic Acid Binding Ig-Like Lectin 15
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques3
Phase de R&D la plus avancéePhase 2 Clinical

Siglec-15 Liste de produits

  • Attribut

    Protein (7)

  • Bibliothèque de produits

    En ligne (7)

  • Espèces

    Human (4)Rhesus macaque (1)Mouse (1)Rat (1)

  • Étiquette

    Fc Tag (1)His Tag (4)His Tag & Avi Tag (1)Fc Tag & Avi Tag (1)

  • Marqueur

    Unconjugated (5)Biotin-labeled (2)

Siglec-15Contexte de la molécule

Siglec-15 is a DAP12-associated immunoreceptor, which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. Siglecs are cell surface proteins that bind sialic acid. They are found primarily on the surface of immune cells and are a subset of the I-type lectins. Siglec-15 consisting of immunoglobulin (Ig)-like domains, transmembrane domain and a short cytoplasmic tail. Siglec-15 is that recognizes sialylated glycans and regulates osteoclast differentiation. Siglec-15 is a potential therapeutic target for osteoporosis and plays a conserved regulatory role in the immune system of vertebrates.

Siglec-15Alias de la molécule

CD33 antigen-like 3,SIGLEC-15,CD33L3,sialic acid-binding Ig-like lectin 15,Siglec15,Siglec-15

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
NC-318NC-318; 5G-12Phase 2 ClinicalYale School Of MedicineBreast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Endometrial Neoplasms; Lung Neoplasms; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
DS-1501DS-1501Phase 1 ClinicalDaiichi Sankyo Co LtdOsteoporosis
Details
BSI-060TPYX-106; BSI-060TPhase 1 ClinicalBiosion IncNeoplasm Metastasis; Solid tumours
Details

Avis sur les produits

  • 1***22019-10-11
    6Mettre un like
    Siglec-15 is a relatively new type of immune checkpoint molecule. In the process of antibody molecule screening, we used ACRO's Siglec-15 antigen. It has shown very good stability in protein-level binding experiments, and the bioactivity was also quite good which was verified in functional experiments.
  • 1***32019-10-11
    1Mettre un like
    The product is pretty good and the price is competitive. Besides, the delivery was fast. In particular, there is a literature introduction cited the product. It is obvious that each target has been carefully studied.
  • 1***22019-10-12
    8Mettre un like
    We can obtain a good inhibitory effect using this protein to verify its inhibitory on T-cells functions. S15-hFc protein can effectively inhibit the secretion of IFN-gamma stimulated by OKT3 in CD4 + T cells.
  • Informations sur la molécule
  • Liste de produits
  • Avis sur les produits
  • Informations sur les médicaments cliniques